SLEEPZ AG — Share Issue/Capital Change 2008

Jul 3, 2008

News Details

Corporate | 3 July 2008 10:45

bmp AG: Successful closing of a round of financing for Revotar AG

bmp AG / Miscellaneous

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

bmp AG: Successful closing of a round of financing for Revotar AG

Berlin, 03.07.2008

bmp AG (ISIN DE003304200) announces, that its portfolio company Revotar
Biopharmaceuticals AG has successfully concluded a round of financing for
just under €4 million. MVC Unternehmensbeteiligungsgesellschaft mbH and
Deutsche Life Science GmbH were additional participants in this round
together with the new investor, IBG Risikokapitalfonds I, which is managed
by Goodvent GmbH. Once the corporate action has been registered in the
Commercial Register, the stake in Revotar held by bmp will amount to 33.19
%.

The funds available due to the financing are intended for the further
clinical development of the core product 'Bimosiamose' and the construction
and development of Revotar’s innovative development pipeline.

Oliver Borrmann, Chairman of the Board of Directors of bmp AG and future
Chairman of the Supervisory Board of Revotar AG says, 'We are proud to have
gained with IBG an experienced investor into biotechnology for Revotar. We
now have the common aim to find further investors for Revotar by the end of
this year, in order to successfully progress with all clinical projects.'

About Revotar Biopharmaceuticals AG:
As a biotechnology company, it researches and develops low-molecular agents
for the treatment of phlogistic diseases as well as psoriasis, acute
pulmonic failure/acute progressive respiratory distress syndrome of adults
(ALI/ARDS) and COPD (chronical obstructive lung disease). The world-wide
best developed pan selektin antagonist bimosiamose, for which Revotar holds
the exclusive rights, has already passed successfully numerous pre-clinical
animal models as well as the clinical stage I and stage IIa in the
indications asthma and psoriasis.
bmp has participated in the company since July 2000.
For further information: www.revotar.de

About bmp AG:
As an internationally operating Private Equity Asset Manager, bmp (ISIN
DE0003304200) is operating in the business areas direct investments and
private equity advisory.
In the area of direct investments bmp advises third parties on investments
into innovative growth companies mainly in Germany and Poland and manages
its own investment vehicles bmp Media Investors AG & Co. KGaA and bmp Eco
Investors GmbH & Co. KGaA. The industry focus of our subsidiaries thereby
rests on media, entertainment and marketing services respectively renewable
energy and clean technology.
To its clients, bmp supplies a comprehensive ten-years' know-how as a
business developer of growth companies. With experience from nearly 100 of
its own investments, 14 initial public offerings, and more than 25 trade
sales from its portfolio, bmp is one of the most competent venture capital
investors in Germany and Poland.
In the area of private equity advisory bmp advises third parties on
investments into international private equity funds. The private equity
fund of funds 'König & Cie. International Private Equity' I and II,
initiated by the Hamburg investment company König & Cie and managed by bmp,
as well as further institutional investors are counted among bmp’s clients.
The asset programs for the clients advised by bmp include investments in
funds in Europe as well as North America an Asia.

For further information:

Corinna Riewe
Investor Relations
criewe@bmp.com

Tel.: 030-20 30 5 567
Fax: 030-20 30 5 555

bmp AG, Schlüterstraße 38, 10629 Berlin

Internet: www.bmp.com
ISIN: DE0003304200

This issue of Corporate News represents neither an offering nor a request
for the tendering of bids for the purchase of securities – particularly not
in the US and not in any countries or jurisdictions in which offers,
requests for the tendering of bids for purchases or for sales would not be
permitted without previous registration or approval in accordance with the
stipulations of the respectively applicable securities regulations.
This issue of Corporate News represents neither an offer for the sale of
individual proprietary shares nor a request for the submission of an offer
for the purchase of individual shares; it is intended solely for
information purposes.
03.07.2008 Financial News transmitted by DGAP

---

Language: English
Issuer: bmp AG
Schlüterstraße 38
10629 Berlin
Deutschland
Phone: +49 (0)30 20 305-0
Fax: +49 (0)30 20 305-532
E-mail: ir@bmp.com
Internet: www.bmp.com
ISIN: DE0003304200
WKN: 330420
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Stuttgart, München, Hamburg, Düsseldorf; Foreign
Exchange(s) Warschau

End of News DGAP News-Service

---